ClinicalTrials.gg
Not yet recruitingNCT07175610LUNETUpdated Sep 16, 2025

LUpus Eritematoso Sistemico NETwork and Registry

An observational study in Systemic Lupus Erythematous (SLE), sponsored by Società Italiana di Allergologia, Asma e Immunologia Clinica. Not yet recruiting at 16 sites in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-09-16.

Sponsored by Società Italiana di Allergologia, Asma e Immunologia Clinica · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
1,500
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 81 studies in Lupus Erythematosus, Systemic with a site in Italy — 23 open to participants now, 41 under way, 18 of them phase 3. Lupus Erythematosus, Systemic · Italy.

Planned enrollment
2nd of 13
1,500 · median 300
Started
2025
with 5 others
Observational
13 of 81
5 open now
Primary completion
2026-12
later than 13 of 40 live
Registered
69th of 81
by date

Among the 81 studies in Lupus Erythematosus, Systemic with a site in Italy, this one is the 2nd largest by planned enrollment of the 13 observational ones that give a count, is one of 6 that started in 2025, is one of 13 observational ones, reaches primary completion later than 13 of the 40 other live ones, and was the 69th registered.

Lupus Erythematosus, Systemic

1,211 studies on the registry are indexed under Lupus Erythematosus, Systemic; 406 are open to participants now.

Browse Lupus Erythematosus, Systemic studies →

Open to participants now

23 of the 81 studies in Lupus Erythematosus, Systemic with a site in Italy are open now. Recruiting first, the newest first:

18 more — sign in →

All 23 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 284 Lupus Erythematosus, Systemic studies recruiting now, 94 (33%) set no upper age limit and 160 (56%) stop at 75 or younger; 54 take children under 18; 32 take healthy volunteers.

This study: 18 Years and older · all sexes.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 81 studies in Lupus Erythematosus, Systemic with a site in Italy, or all of them as a file.
02

Study summary

The LUNET Registry is intended to serve as a comprehensive primary data source, capturing real-world longitudinal clinical information, and the heterogeneity of patient presentations that are often underrepresented in traditional clinical trials. Ultimately, the LUNET Registry will help to optimize SLE management in routine clinical practice by enabling the compilation of real-world evidence to inform clinical decision-making and health policy. Patients will be enrolled by secondary and tertiary care centres for SLE across Italy in a real-world clinical set-up.

Read the detailed description

The LUNET's specific objectives are as follows:

  • Planning and conducting epidemiological studies to evaluate the incidence and prevalence rates of different clinical manifestations of SLE, and to evaluate short- and long-term outcomes, including survival rates and organ dysfunction, injury, and failure
  • Promoting multicenter studies that will compare different patient subgroups based on clinical phenotypes and organ involvement, to attain insights regarding disease expression and progression
  • Describing the profile of patients with lupus nephritis in the national population, to improve guidelines on its systematic and standardized assessment.
  • Evaluating the presence of central and peripheral nervous system involvement in the national population of patients with SLE, assessing the type, frequency, and severity of neurological symptoms and objective signs, as well as the instrumental techniques used in clinical practice (e.g., Magnetic Resonance Imaging (MRI)
  • Assessing biomarker data to support early diagnosis and guide treatment choices
  • Improving screening techniques for early identification of organ damage in SLE patients
  • Improving early treatment strategies
  • Tracking adherence and response to therapy
  • Evaluating the short- and long-term real-life effectiveness and safety of old and novel drugs approved for SLE, overall and in groups of patients with specific phenotypes
  • Assessing SLE patients' quality of life according to clinical phenotype and treatment approach
  • Assessing how socioeconomic status impacts patients' access to healthcare and absenteeism in relation to the disease and various therapeutic approaches
  • Evaluating how different therapeutic strategies impact hospitalization
  • Assessing the influence of old and novel therapies on fertility, pregnancy, and breastfeeding
  • Monitoring cardiovascular risk in SLE patients by evaluating the associated comorbidities, prospective development of cardiovascular events, and biomarker levels (e.g., fasting blood glucose, hemoglobin A1c, total cholesterol, HDL cholesterol, LDL cholesterol, triglycerides and pro-BNP)
  • Evaluating bone metabolism in patients with SLE through assessment of laboratory measurements (e.g., vitamin D, calcium, phosphorus, calcinuria, and phosphaturia) and instrumental assessments, such as dual-energy X-ray absorptiometry (DEXA) scans
  • Monitoring the causes of death among SLE patients
03

Conditions studied

  • Systemic Lupus Erythematous (SLE)

Keywords

  • Systemic Erythematosus Lupus
  • Connective Tissue Diseases
  • Autoimmune Diseases
  • mmune System Diseases
  • Biologic Therapies
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Sampling method
Probability sample

Study population

Patients with SLE according to the SLICC 2012 and/or ACR/EULAR 2019 classification criteria

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • age ≥ 18 years;
  • confirmed SLE diagnosis according to the SLICC 2012 and/or ACR/EULAR 2019 classification criteria;
  • provision of signed written prior to participation

Exclusion criteria

Exclusion Criteria:

-

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
1,500 participants (estimated)
Target follow-up
10 Years
Patient registry
Yes
06

What researchers measure

Primary outcomes

  1. Remission

    Number of patients who achieved complete clinical remission or low disease activity

    Time frame: Every year to ten year

  2. Disease activity

    Changes in disease activity (SLEDAI-2k)

    Time frame: Every year to ten year

07

Study locations

16 sites
  • SOD Clinica Medica, Dip. Medicina Interna- Ospedali Riuniti Marche-AOU delle Marche
    Ancona, Italy
    • Gianluca Moroncini · Principal investigator
  • Medicina Interna Universitaria (Guido Baccelli) Azienda Ospedaliera Policlinico Consorziale
    Bari, Italy
    • Angelo Vacca · Principal investigator
  • U.O. di Medicina, Ospedale Civile "Santa Maria della Sapienza"
    Battipaglia, Italy
    • Vincenzo Patella · Principal investigator
  • Allergologia e Immunologia Clinica, Azienda Ospedaliero-Universitaria di Cagliari
    Cagliari, Italy
    • Stefano Del Giacco · Principal investigator
  • Struttura organizzativa Dipartimentale Complessa Immunologia e Terapie Cellulari, A.O.U. Careggi
    Florence, Italy
    • Paola Parronchi · Principal investigator
  • Struttura complessa Allergologia Immunologia Clinica e Reumatologia.Azienda Socio Sanitaria Territoriale di Mantova
    Mantua, Italy
    • Maria Teresa Costantino · Principal investigator
  • Unità di Immunologia, Reumatologia, Allergologia e Malattie Rare all'IRCCS Ospedale San Raffaele di Milano
    Milan, 20132, Italy
    • Lorenzo Dagna · Principal investigator
  • Division of Internal Medicine and Clinical Immunology, Azienda Ospedaliera Universitaria Federico II
    Naples, Italy
  • SYNERGO - Institute of Clinical Immunotherapy and Advanced Biological Treatmets-Casa di Cura Pierangeli S.r.l.
    Pescara, Italy
  • UO Immunoallergologia clinica, Azienda Ospedaliero Universitaria Pisana
    Pisa, Italy
    • Valentina Pucino · Principal investigator
  • UOC di Medicina Interna e Nutrizione Clinica -Policlinico Umberto I
    Roma, Italy
  • Reumatologia e Immunologia Clinica, Humanitas Research Hospital
    Rozzano, Italy
    • Carlo Francesco Selmi · Principal investigator
  • UOC Clinica Immunologica e Reumatologica, A.O.U. San Giovanni di Dio e Ruggi d'Aragona
    Salerno, Italy
    • Massimo Triggiani · Principal investigator
  • SC (U.C.O.) Medicina Clinica Azienda Sanitaria Universitaria Giuliano Isontina (ASU GI)
    Trieste, Italy
    • Giacomo Emmi · Principal investigator
  • SCDU Immunologia e Allergologia AO Ordine Mauriziano, University of Turin
    Turin, 10128, Italy
    • Luisa Brussino · Principal investigator
    • Simone Negrini · Sub investigator
  • Medicina Interna B - Azienda Ospedaliera Universitaria Integrata
    Verona, Italy
    • Simonetta Friso · Principal investigator
08

References and documents

Publications

  • Mormile I, Brussino L, Canonica GW, Cortini F, Costantino MT, Dagna L, Del Giacco S, Della Casa F, Di Gioacchino M, Emmi G, Moroncini G, Negrini S, Pacella D, Parronchi P, Patella V, Rossi FW, Sirena C, Triggiani M, Vacca A, de Paulis A. The LUNET Project: Developing the Italian Systemic Erythematous Lupus Network. J Clin Med. 2025 Sep 2;14(17):6197. doi: 10.3390/jcm14176197. PubMed 40943959 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Sep 2025; primary completion for Dec 2026, 15 months later.

Of 90 non-industry observational studies under Lupus Erythematosus, Systemic, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 212. This study's planned 15 months is below that.

Counting every sponsor, half of 112 studies reached it within 64 months; a quarter within 30 and three quarters within 126.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 9, 2025
First posted
Sep 16, 2025
StartEst.
Sep 30, 2025
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2035
Last update
Sep 16, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 16, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07175610
Lead sponsor
Società Italiana di Allergologia, Asma e Immunologia Clinica
Responsible party
Sponsor
First posted
Sep 16, 2025
Start date
Sep 30, 2025 (estimated)
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2035 (estimated)
Last update
Sep 16, 2025

Study contacts

Concetta Sirena
Contact
ricerche@siaaic.org
+39 02 4969 5358
Amato de Paulis
study chair · Division of Internal Medicine and Clinical Immunology, Center for Basic and Clinical Immunology Research (CISI), University of Naples Federico II, Naples, Italy

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion